Literature DB >> 15861176

How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

J Hasford, M Pfirrmann, A Hochhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15861176     DOI： 10.1038/sj.leu.2403686

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  The effects of imatinib on pregnancy outcome.

Authors:  Seonaid M Pye; Jorge Cortes; Patricia Ault; Alan Hatfield; Hagop Kantarjian; Richard Pilot; Gianantonio Rosti; Jane F Apperley
Journal:  Blood       Date:  2008-03-05       Impact factor: 22.113

2.  Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Authors:  Luis-Felipe Casado; José-Valentín García-Gutiérrez; Isabel Massagué; Pilar Giraldo; Manuel Pérez-Encinas; Raquel de Paz; Joaquín Martínez-López; Guiomar Bautista; Santiago Osorio; María-José Requena; Luis Palomera; María-Jesús Peñarrubia; Carmen Calle; José-Ángel Hernández-Rivas; Carmen Burgaleta; Begoña Maestro; Nuria García-Ormeña; Juan-Luis Steegmann
Journal:  Cancer Med       Date:  2015-03-10       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.